The new analgesic tapentadol was evaluated for induction and inhibition of several cytochrome P450 enzymes in vitro, and protein binding was assessed. It was concluded that no clinically relevant drug – drug interactions are likely to occur through either mechanism.
Keywords: protein binding, CYP isoforms, Hepatocytes, omeprazole, glucuronidation
open access plus
Rights & PermissionsPrintExport